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Objectives
The aims of this study were to identify temporal trends in the incidence of sexually transmitted
diseases (STDs) in a cohort of HIV-infected people and to evaluate factors associated with the
risk of a new STD diagnosis.
Methods
All HIV-infected patients in the Icona Foundation Study cohort enrolled after 1998 were
included in this study. STD incidence rates (IRs) were calculated and stratified by calendar
period. Predictors of STDs were identified using a Poisson regression model with sandwich
estimates for standard errors.
Results
Data for 9168 participants were analysed [median age 37.3 (range 18–81) years; 74% male; 30%
men who have sex with men (MSM)]. Over 46 736 person-years of follow-up (PYFU), 996
episodes of STDs were observed [crude IR 21.3/1000 PYFU; 95% confidence interval (CI)
20.0–22.6/1000 PYFU]. In multivariable Poisson regression analysis, MSM [rate ratio (RR) 3.03;
95% CI 2.52–3.64 versus heterosexuals], calendar period (RR 1.67; 95% CI 1.42–1.97 for
2008–2012 versus 1998–2002), HIV RNA > 50 HIV-1 RNA copies/mL (RR 1.44; 95% CI 1.19–1.74
versus HIV RNA ≤ 50 copies/mL) and a current CD4 count < 100 cells/μL (RR 4.66; 95% CI
3.69–5.89; P < 0.001 versus CD4 count > 500 cells/μL) were associated with an increased risk of
STDs. In contrast, older age (RR 0.82 per 10 years older; 95% CI 0.77–0.89) and being currently
on ART (RR 0.38; 95% CI 0.33–0.45) compared with being ART-naïve or on a treatment
interruption were associated with a lower risk of developing STDs.
Conclusions
An increase in the incidence of STDs was observed in more recent years. Interventions to
prevent STDs and potential spread of HIV should target the younger population, MSM and
people currently not receiving ART.
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Introduction
The role of fully suppressive combination antiretroviral
therapy (cART) in reducing HIV transmission to HIV-
negative partners is well established [1,2], and model simu-
lations show that a policy based on timely identification
and increased access to antiretroviral therapy may even-
tually lead to control of the HIV/AIDS epidemic [3].
However, the impact of ART on the spread of the epidemic
has to date been at best limited, even in resource-rich
countries, and it has been suggested that persistent risky
behaviour, such as condom-less sex, may contribute to
limit the beneficial effect of cART in reducing the incidence
of HIV infection, at least in men who have sex with men
(MSM) in the UK [4]. Concern has also been expressed that
provision of ART may per se be associated with an increase
in the rate of condom-less sex, as a result of so-called risk
compensation, although a systematic review of available
evidence did not support this hypothesis, but instead dem-
onstrated that the probability of engaging in unprotected
sex was associated with the belief that ART may prevent
viral transmission, rather than with actual receipt of ART
or viral suppression per se [5].
In this context, the analysis of the possible determinants
of sexually transmitted diseases (STDs) among persons
living with HIV may help to identify populations that are
likely to engage in these risky behaviours. It has also been
shown that STDs can increase the shedding of HIV in
semen, leading to an increase of HIV transmission [6].
However, this phenomenon was demonstrated in people
not receiving cART, and it remains largely unknown
whether the same increase in the risk of STDs might be seen
in people on fully suppressive cART. In addition, it has
been recently demonstrated that effective cART does not
completely reduce the risk of HIV transmission in sexually
active MSM with concomitant STDs [7].
The Icona Foundation Study is an observational study
enrolling HIV-infected patients naïve to ART over the
period 1997–2014, and a previous analysis performed
using the data from this cohort demonstrated that the use
of cART was not associated with the risk of newly acquired
hepatitis B virus (HBV) infection and syphilis, and that
suppressive cART was associated with a lower risk of HBV
surface antigen (HBsAg) seroconversion [8].
In the present analysis, we adopted a more comprehen-
sive approach considering all incident STDs. Moreover, as
it has been estimated that more than 85% of patients
treated with cART in Italy are currently on fully suppres-
sive cART and some of the patients in the cohort have now
been followed up for over 15 years, we decided to perform
this more comprehensive analysis focused on the role of
current viral loads and extended to more recent years to
provide updated data that might be useful in plann-
ing STD prevention programmes aiming to reduce HIV
transmission.
Specifically, we aimed to identify temporal trends in
the incidence of STDs and to evaluate factors associated
with the risk of a new diagnosis of an STD, with particular
focus on the use of cART and the possible role of viral
suppression.
Methods
All HIV-infected patients enrolled in the Icona Foundation
Study cohort from 1998 were included in our analysis. The
Icona Foundation Study is an observational cohort study of
HIV-infected individuals who are antiretroviral-naïve at
the time of enrolment [9]. This cohort was set up in January
1997 and currently includes data on patients enrolled at 40
infectious disease units in Italy. Initiation and discontinu-
ation dates of each antiretroviral drug, the HIV viral load
and CD4 cell count at each clinical visit (every 4–6 months
on average), and clinical HIV- and non-HIV-related events
are recorded in the database. Data on STDs are available at
enrolment and they are updated at the occurrence of any
clinical event or, in their absence, at least every 6 months.
In this analysis, STD occurrence was defined at the
date of clinical diagnosis of any of the following condi-
tions: any-stage syphilis (primary, secondary, latent,
tertiary or unspecified), human papilloma virus (HPV)-
related diseases, urethritis (gonococcal or nongonococcal),
herpes simplex virus (HSV)-related genital ulcers, any
genital ulcer disease not otherwise specified, vaginitis
(trichomonas, bacteric or not specified), or acute HBV,
hepatitis A virus (HAV) or hepatitis C virus (HCV) infection.
These conditions and not others were selected as they are
routinely reported by clinicians enrolling patients in the
cohort with reasonable accuracy. All episodes of STD
counted as an event so that the same person could have
contributed more than one event. Only true incident cases
of STD were included as events, by considering only those
that occurred at least 12 months after the date of enrolment
in the cohort.
STD incidence rates (IRs) were calculated as the number
of events divided by person-years of follow-up (PYFU).
These rates were stratified according to a number of
factors, including current plasma viral load (plasma HIV
RNA < 50 HIV-1 RNA copies/mL versus > 50 copies/mL)
and calendar period (1998–2002, 2003–2007 and 2008–
2012). Other factors considered were age (stratified as
18–30, 31–40, 41–50, 51–60 and > 60 years old), gender,
risk behaviour for HIV transmission [heterosexual, men
who have sex with men (MSM), injecting drug user (IDU)
and unknown/other], educational level (primary, secondary
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school, college and university), ethnicity (Caucasian,
black, Hispanic, Asian and other), current CD4 count
(< 100, 101–350, 351–500 and > 500 cells/uL), ART status
(ART-naïve, on ART and on treatment interruption at STD
diagnosis). ART was defined as a regimen of at least one
drug belonging to one of the three major historical drug
classes [nucleoside reverse transcriptase inhibitor (NRTI),
nonnucleoside reverse transcriptase inhibitor (NNRTI) and
protease inhibitor (PI)]. Independent predictors of STD
occurrence were identified using a Poisson regression
model. Sandwich estimates for the standard errors were
used to control for the fact that some people might have
contributed more than one event.
Because hepatitis is most frequently acquired via needle
sharing rather than through sexual contacts, two sensitiv-
ity analyses were performed to assess the role of behav-
ioural risks, (i) not counting as events all diagnoses of
hepatitis and (ii) not counting as events the diagnoses of
hepatitis that occurred in IDUs.
All individuals signed an informed consent form prior
to enrolment and the study was approved by the Ethics




A total of 9168 patients were included in the analysis 2355
(25.7%) of whom were women. The median age at enrol-
ment was 37.3 years (range 18–81 years) and the median
CD4 count was 387 cells/μL [interquartile range (IQR) 196–
576 cells/μL]. Regarding risk behaviours, MSM represented
31.1% of the study population (n = 2850), IDU 24.3%
(n = 2226) and heterosexual contact 38.4% (n = 3518). A
total of 3327 patients were enrolled in 1998–2002, 1273
in 2003–2007 and 4568 in 2008–2012. By definition, all
patients were ART-naïve at enrolment but 70.8% of them
started ART over the study period.
Incidence of STDs
Over 46 736 PYFU, 996 diagnoses of STDs were reported in
945 patients [crude IR 21.3/1000 PYFU; 95% confidence
interval (CI) 20.0–22.6/1000 PYFU]. Forty-eight patients
(0.5%) contributed more than one episode of incident STD
(45 patients with two episodes and three patients with three
episodes).
Considering specific STDs, any-stage syphilis had a
crude IR of 3.95/1000 PYFU (95% CI 3.59–4.35/1000
PYFU), HPV infection 1.96 (95% CI 1.71–2.24), acute viral
hepatitis 1.72 (95% CI 1.49–1.99) [HAV 0.19 (95% CI 0.09–
0.36), HBV 6.54 (95% CI 5.83–7.32), and HCV 3.74 (95% CI
3.21–4.34)], HSV infection 0.81 (95% CI 0.65–0.99), gono-
coccal uretritis 0.46 (95% CI 0.35–0.61), nongonococcal
uretritis 0.47 (95% CI 0.36–0.62) and other genital ulcers
0.11 (95% CI 0.06–0.19).
As shown in Table 1, a higher IR of STDs was observed
in men compared with women [24.1/1000 PYFU (95% CI
22.4–25.8/1000 PYFU) versus 14.6/1000 PYFU (95% CI
12.7–16.8/1000 PYFU), respectively] and in people aged
18–30 years compared with the other age strata [45.4/1000
Table 1 Crude incidence of sexually transmitted diseases (STDs) in the
whole population (n = 9168)
Number of
events PYFU IR (95% CI)
Women 204 13912 14.6 (12.7–16.8)
Men 792 32824 24.1 (22.4–25.8)
Age
18–30 years 181 3982 45.4 (39.0–52.5)
31–40 years 441 18421 23.9 (21.7–26.2)
41–50 years 276 16992 16.2 (14.3–18.2)
51–70 years 93 7021 13.2 (10.7–16.2)
> 70 years 5 329 15.1 (4.9–35.4)
HIV transmission route
Heterosexual 229 18557 15.7 (13.9–17.6)
MSM 561 10843 51.7 (47.5–56.2)
IDU 87 14926 5.8 (4.6–7.1)
Other 56 2410 23.2 (17.5–30.1)
Period of STDs
1998–2002 272 15745 17.2 (15.2–19.4)
2003–2007 269 15399 17.4 (15.4–19.6)
2008–2012 455 15592 29.1 (26.5–31.9)
CD4 count at STD diagnosis
> 500 cells/μL 457 24789 18.4 (16.7–20.2)
351–500 cells/μL 203 10765 18.8 (16.3–21.6)
101–350 cells/μL 247 9832 25.1 (22.0–28.4)
< 100 cells/μL 89 1350 65.9 (52.9–81.1)
HIV RNA at STD diagnosis
< 50 copies/mL 174 16289 10.6 (9.1–12.3)
> 50 copies/mL 822 30446 27.0 (25.1–28.9)
Years since HIV diagnosis
< 10 years 860 28932 29.7 (27.7–31.7)
11–20 years 122 14956 8.1 (6.7–9.7)
> 20 years 11 2680 4.1 (2.0–7.3)
Missing 3 168 18.8 (3.6–52.1)
Education
Primary 79 4393 17.98 (14.2–22.4)
Secondary 248 16531 15.00 (13.2–17.0)
College 349 12855 27.15 (24.4–30.1)
University 113 2614 43.23 (35.6–52.0)
Missing 207 10343 20.01 (17.4–22.9)
Ethnicity
Caucasian 909 44132 20.60 (19.3–22.0)
Afro-American 34 1364 24.93 (17.2–34.8)
Hispanic 45 968 46.50 (33.9–62.2)
Asian 8 217 36.91 (15.9–72.6)
ART status
Naïve 534 11962 44.64 (40.9–48.6)
On ART 400 31297 12.78 (11.5–14.1)
On treatment interruption 62 3478 17.83 (13.6–22.8)
ART, antiretroviral therapy; CI, confidence interval; IDU, injecting drug use;
IR, incidence rate; MSM, men who have sex with men; PYFU, person-years
of follow-up.
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PYFU (95% CI 39.0–52.5/1000 PYFU) versus 23.9 (95% CI
21.7–26.2) for 31–40 years, 16.2 (95% CI 14.3–18.2) for
41–50 years, 13.2 (95% CI 10.7–16.2) for 51–70 years and
15.1 (95% CI 4.9–35.4) for > 70 years].
More than half of all episodes of STDs (561 of 996)
occurred among MSM, for whom the STD incidence was
more than twice as high as that recorded in the other
transmission groups [unadjusted rate ratio (RR) 3.29; 95%
CI 2.85–3.79; P < 0.001]. STD incidence increased in
very recent years; in particular, the IR seemed to be stable
over the period 2000–2008, with a marked increase
observed after 2008 (unadjusted RR 1.69; 95% CI 2.85–
3.79; P < 0.001). Nevertheless, when the incidence in the
different study periods was analysed separately for trans-
mission categories (Fig. 1), MSM had the highest incidence
in all time periods. Moreover, the difference in the risk of
STDs between MSM and other transmission categories was
not consistent over time periods (higher in more recent as
opposed to less recent years), supporting the role of MSM
in driving the increase in the STD incidence, especially in
recent years (P-value of likelihood ratio test 0.002) (Fig. 1).
Four hundred episodes of STDs (40%) occurred while
people were on ART (IR 12.8/31 297 PYFU), 534 (53%) in
ART-naïve patients (IR 44.6/11 961 PYFU) and 62 in those
who had discontinued ART (IR 17.8/3478 PYFU). Patients
in whom plasma HIV RNA was < 50 copies/mL had an STD
incidence that was roughly one-third of that observed
among patients with a detectable plasma HIV RNA [IR
10.6/1000 PYFU (95% CI 9.1–12.3/1000 PYFU) versus 27.0/
1000 PYFU (95% CI 25.1–28.9/1000 PYFU), respectively;
unadjusted RR 1.44; 95% CI 1.19–1.74; P < 0.001].
As shown in Table 2, after adjusting for age, HIV trans-
mission route, current calendar period, years from HIV
diagnosis, current CD4 count and HIV RNA, and level
of education, to be MSM (RR 3.03; 95% CI 2.52–3.64;
P < 0.001 compared with other routes of HIV transmission),
to have a current CD4 count < 100 cells/μL (RR 4.66; 95%
CI 3.69–5.89; P < 0.001 compared with higher strata of CD4
count), to have uncontrolled plasma HIV RNA (RR 1.44;
95% CI 1.19–1.74; P < 0.001 compared with viraemia < 50
copies/mL), and to be diagnosed with HIV infection in
recent years (< 10 years ago versus > 10 years: RR 2.70;
95% CI 1.45–5.03; P = 0.002) were all factors indepen-
dently associated with the risk of acquiring an STD.
Moreover, more recent calendar period (2008–2012) was
also independently associated with an increased risk of
Fig. 1 Incidence rate for any sexually transmitted disease (STD) according to HIV transmission route in different periods of observation. IDU, injecting
drug use; MSM, men who have sex with men.
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developing an STD (RR 1.67; 95% CI 1.42–1.97; P < 0.001
compared with previous years of observation).
A significantly reduced risk of an STD was reported for
people with a previous history of ART use (RR 0.38; 95% CI
0.33–0.45; P < 0.001 compared with people who had never
used ART) (Table 2). Nevertheless, when the current status
of ART-experienced individuals was further classified as
current use and temporary suspension, wide differences in
terms of IR of STD were observed: 12.8/1000 PYFU in
people currently receiving ART, 44.6/1000 PYFU in people
who were ART-naïve, and 17.8/1000 PYFU for people on
temporary ART interruption.
In terms of RRs, compared with ART-naïve patients,
the RR for any STD was significantly lower for people
currently receiving ART (RR 0.28; 95% CI 0.25–0.32;
P < 0.001) as well as for people previously exposed to ART,
but currently on a temporary interruption (RR 0.40; 95% CI
0.31–0.52; P < 0.001).
When we performed a multivariable analysis stratified
by ART status (ART-naïve, on ART or on treatment inter-
ruption), the same associations found in the whole popu-
lation (Table S1) were found among ART exposure
categories for transmission route as well as for period of
STD diagnosis.
Table 2 Unadjusted and adjusted incidence rate ratios (IRRs) for developing sexually transmitted diseases (STDs) in the whole population
Unadjusted IRR 95% CI P Adjusted IRR 95% CI P
Women 1 1
Men 1.64 1.41–1.92 < 0.001 0.88 0.72–1.09 0.21
Age
18–30 years 1 1
31–40 years 0.53 0.44–0.63 < 0.001 0.89 0.74–1.06 0.19
41–50 years 0.36 0.29–0.43 < 0.001 0.75 0.62–0.92 0.005
51–70 years 0.29 0.23–0.37 < 0.001 0.52 0.40–0.67 < 0.001
> 70 years 0.33 0.14–0.81 0.01 0.56 0.23–1.37 0.20
HIV transmission route
Heterosexual 1 1
MSM 3.23 2.85–3.79 < 0.001 3.03 2.52–3.64 < 0.001
IDU 0.82 0.68–0.98 0.030 0.51 0.39–0.66 < 0.001
Other 1.50 1.12–2.00 0.006 1.54 1.15–2.07 0.004
Period of STDs
1998–2002 1 1
2003–2007 1.01 0.85–1.19 0.89 1.16 0.98–1.38 0.08
2008–2012 1.69 1.45–1.96 < 0.001 1.67 1.42–1.97 < 0.001
CD4 count at STD diagnosis
> 500 cells/μL 1 1
351–500 cells/μL 1.02 0.86–1.21 0.78 0.94 0.79–1.11 0.45
101–350 cells/μL 1.36 1.16–1.59 < 0.001 1.63 1.39–1.91 < 0.001
< 100 cells/μL 3.57 2.85–4.48 < 0.001 4.66 3.69–5.89 < 0.001
HIV RNA at STD diagnosis
< 50 copies/mL 1 1
> 50 copies/mL 2.53 2.14–2.97 < 0.001 1.44 1.19–1.74 < 0.001
Years since HIV diagnosis
> 20 years 1 1
11–20 years 1.98 1.07–3.68 0.029 1.43 0.76–2.67 0.265
< 10 years 7.24 3.99–13.12 < 0.001 2.70 1.45–5.03 0.002
Missing 4.34 1.21–15.56 0.024 0.95 0.26–3.48 0.947
Education
Primary 1 1
Secondary 0.83 0.64–1.07 0.16 0.76 0.59–0.99 0.04
College 1.50 1.18–1.92 0.001 0.89 0.68–1.15 0.37
University 2.40 1.80–3.20 < 0.001 0.93 0.68–1.26 0.65
Missing 1.11 0.86–1.44 0.41 0.70 0.53–0.91 0.01
Ethnicity
Caucasian 1 1
Afro-American 1.21 0.85–1.70 0.27 1.00 0.70–1.43 0.98
Hispanic 2.25 1.67–3.04 < 0.001 1.07 0.79–1.46 0.62
Asian 1.79 0.89–2.67 0.10 1.34 0.66–2.70 0.40
ART status
Naïve 1 1
On ART 0.28 0.25–0.32 < 0.001 0.37 0.32–0.43 < 0.001
On treatment interruption 0.40 0.31–0.52 < 0.001 0.51 0.39–0.67 < 0.001
ART, antiretroviral therapy; CI, confidence interval; IDU, injecting drug use; MSM, men who have sex with men.
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Finally, to determine the possible impact of the exclusion
of viral hepatitis from STDs for IDUs, we repeated the
Poisson regression analysis after excluding viral hepatitis
from the definition of an STD event. In this analysis, the
association between transmission group and STD incidence
was similar to that in the whole cohort: for MSM versus
heterosexual, the incidence rate ratio (IRR) was 3.17 (95%
CI 2.71–3.72; P < 0.001), for IDU versus heterosexual, the
IRR was 0.45 (95% CI 0.35–0.58; P < 0.001), and for other
risks versus heterosexual, the IRR was 1.44 (95% CI 1.04–
2.00; P = 0.026). Similar results were found in the second
sensitivity analyses: for MSM versus heterosexual, the
IRR was 3.29 (95% CI 2.85–3.78; P < 0.001), for IDU versus
heterosexual, the IRR was 0.37 (95% CI 0.29–0.47;
P < 0.001), and for other risks versus heterosexual, the IRR
was 1.50 (95% CI 1.12–2.00; P = 0.006).
Discussion
The results of our analysis show that the risk of acquiring
a new STD in HIV-infected individuals has been increasing
over time. This is especially true in young people, in MSM,
in people currently with a low CD4 count, in those recently
diagnosed with HIV infection, and in patients currently not
receiving ART. In particular, the increase in incidence
observed in MSM compared with other HIV transmission
groups seemed more marked in more recent calendar years.
Similar data have been obtained in other cohorts enrolling
subjects from sites located in other geographical areas [10].
This is certainly alarming, as the occurrence of a new STD
has been generally reported to be deleterious for the health
of people living with HIV, as a consequence of various
mechanisms, such as an increased risk of HIV reinfection
caused by either the disruption of mucosal barriers or the
recruitment of activated CD4 cells to the genital tract,
thereby increasing the pool of cells susceptible to HIV
infection; moreover, proinflammatory cytokine release as a
result of STDs may also facilitate HIV entry into cells and
provide a perfect environment for its propagation [11,12];
and a significant acute decrease in CD4 count and increase
in plasma HIV RNA have been reported during syphilis
infection [13,14]. Moreover, although a correlation with
an increased risk of HIV transmission has not been reported
for all STDs, infection with some agents (herpes viruses,
Treponema pallidum, Trichomonas vaginalis, Neisseria
gonorrhoeae and Chlamidia) has been shown to have an
important impact on HIV shedding [15–18]. Of note, the
most frequent STDs observed in our cohort were syphilis and
HPV-related mucosal damage, which are both associated
with an increased risk of HIV transmission [19].
In our analysis, the increased STD incidence in recent
periods was significantly higher in MSM compared with
other transmission groups. This has also been widely
reported [20–22] and it has been hypothesized to be related
to several factors, such as the perception of a reduced risk
of HIV transmission because of the availability of potent
HIV treatment, the increasing use of erectile dysfunction
agents which is known as a practice at highest risk of HIV
acquisition or transmission [23], and the use of recreational
drugs [24].
Moreover, the high prevalence of condom-less sex
among the MSM community has been widely reported
elsewhere: it was as high as 30% in US HIV-infected MSM
[25], which is three-fold higher than that observed among
HIV-uninfected MSM [26,27] and two-fold higher than that
in HIV-infected men who have sex with women [28]. This
fact could explain the spread of STDs among this group of
individuals, in view of the protective role of condoms in
preventing all STDs, not only HIV infection.
In a recently published analysis of HIV-infected patients
in a cohort of MSM in Boston, a high prevalence of STDs
and genital inflammation was reported, even in people on
suppressive cART, and the presence of an STD/urethritis
was independently identified as a predictor of seminal HIV
detection, as well as of an increased likelihood of having
unprotected anal sex with an HIV-infected partner [7].
The finding of a higher incidence of STDs in young people
and in MSM is consistent with that reported in other cohorts
in North America [10,29], and suggests that, in order to be
maximally effective, specific intervention programmes for
HIV prevention should be focused on young, recently diag-
nosed MSM, who might not have had sufficient health care
contact to receive intensive prevention counselling.
Another key finding was that ART reduces the risk of
acquiring an STD. It has been suggested that being on ART
may represent a proxy for retention in care: people on ART
are likely to be those with more stable follow-up, and those
who receive more appropriate and efficacious prevention
counselling or ‘positive prevention’ counselling regarding
the risk of transmitting HIV infection and acquiring other
STDs. ‘Positive prevention’ is defined as a set of strategies
that help people living with HIV to live longer and
healthier lives (1) by preserving their sexual and reproduc-
tive health and avoiding other STDs; (2) by delaying HIV
disease progression; (3) by promoting shared responsibility
to preserve their sexual health and reduce the risk of
HIV transmission [30]. In contrast, people who remain
untreated are typically seen for care less regularly as a
result of either less clinical need or lower adherence to
visits. Then, of course, there is the group of people who are
untreated because they are not even aware of being
infected, and these individuals are likely to be responsible
for a large proportion of new infections [31]. An alternative
hypothesis is that ART may have a protective role against
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the acquisition of STDs via the reduction of plasma HIV
RNA and consequently of genital HIV RNA concentrations
[6].
This is a highly controversial issue. In the HIV Preven-
tion Trial Network 052, in which a large reduction (96%) of
HIV transmission to HIV-negative partners in people start-
ing cART early [1] was reported, the observed prevalence of
STDs was very low (5%), as also was the prevalence of
homosexual couples (3%).
Several recent studies reported persistent seminal HIV RNA
in people on ART despite viral suppression in plasma, with
persistent risk of HIV transmission [32,33], suggesting the
compartmentalization of HIV in the male tract. Nevertheless,
more recently, the results of the PARTNER trial, in which more
than 40% of couples were MSM, showed no episodes of HIV
transmission in the discordant couples, even in the presence of
a high prevalence of STDs [34].
Our study showed that patients currently on ART were at
a reduced risk of STDs compared not only with those who
had never started treatment but also with those who, after
initiating ART in the past, were currently on a temporary
treatment interruption. These results seem to favour the
hypothesis that being on ART represents a proxy for reten-
tion in care; in fact, we found that ART has a protective role
for STDs which cannot be explained solely by currently
having a suppressed plasma viral load. Further analyses are
needed to investigate whether a longer duration of viral
suppression in plasma may lead to a lower risk of transmis-
sion by decreasing the level of HIV RNA in the genital tract
or by other mechanisms that our current analysis could not
explore. Also, the role of STDs in the risk of acquiring HIV
infection could not be directly addressed in our analysis.
In conclusion, we observed a markedly increased inci-
dence of STDs in HIV-infected individuals seen for care in
Italy and identified a number of factors associated with this
increased incidence. Our results should help in guiding a
wide range of interventions aimed at preventing STDs and
reducing the potential further spread of HIV infection
through efforts to increase linkage and retention in care,
and through interventions targeting youth and MSM, as
well as people recently diagnosed with HIV infection and
those with advanced HIV infection.
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